1. Home
  2. MIST vs HNNA Comparison

MIST vs HNNA Comparison

Compare MIST & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • HNNA
  • Stock Information
  • Founded
  • MIST 2003
  • HNNA 1989
  • Country
  • MIST Canada
  • HNNA United States
  • Employees
  • MIST N/A
  • HNNA N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • HNNA Investment Managers
  • Sector
  • MIST Health Care
  • HNNA Finance
  • Exchange
  • MIST Nasdaq
  • HNNA Nasdaq
  • Market Cap
  • MIST 98.1M
  • HNNA 82.4M
  • IPO Year
  • MIST N/A
  • HNNA N/A
  • Fundamental
  • Price
  • MIST $0.88
  • HNNA $10.35
  • Analyst Decision
  • MIST Strong Buy
  • HNNA
  • Analyst Count
  • MIST 2
  • HNNA 0
  • Target Price
  • MIST $17.00
  • HNNA N/A
  • AVG Volume (30 Days)
  • MIST 4.5M
  • HNNA 10.3K
  • Earning Date
  • MIST 03-13-2025
  • HNNA 05-07-2025
  • Dividend Yield
  • MIST N/A
  • HNNA 5.31%
  • EPS Growth
  • MIST N/A
  • HNNA 75.66
  • EPS
  • MIST N/A
  • HNNA 1.12
  • Revenue
  • MIST N/A
  • HNNA $33,210,000.00
  • Revenue This Year
  • MIST N/A
  • HNNA N/A
  • Revenue Next Year
  • MIST $1,105.43
  • HNNA N/A
  • P/E Ratio
  • MIST N/A
  • HNNA $9.36
  • Revenue Growth
  • MIST N/A
  • HNNA 38.27
  • 52 Week Low
  • MIST $0.75
  • HNNA $6.60
  • 52 Week High
  • MIST $2.75
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • MIST 30.59
  • HNNA 37.97
  • Support Level
  • MIST $1.86
  • HNNA $10.35
  • Resistance Level
  • MIST $2.36
  • HNNA $10.90
  • Average True Range (ATR)
  • MIST 0.23
  • HNNA 0.38
  • MACD
  • MIST -0.06
  • HNNA 0.04
  • Stochastic Oscillator
  • MIST 7.43
  • HNNA 63.82

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: